Rejuva Gene Therapy Platform
Rejuva is preclinical and has yet to be assessed by regulatory agencies.
T2D PROGRESSION IS DRIVEN BY DECLINING PANCREATIC FUNCTION AND INSULIN PRODUCTION
PANCREATIC GENE THERAPY (PGTx) TO IMPROVE ISLET FUNCTION
REJUVA IS A MODULAR PHYSIOLOGIC GENE THERAPY WITH 3 KEY ELEMENTS
Leverage our proprietary system to enable local, low dose virus delivery directly to pancreas
Vectors with high transduction efficiency and limited systemic biodistribution
Durable alteration of metabolic hormone response in the islets with tissue-restricted transgenes